Welcome to our dedicated page for Diagnos news (Ticker: DGNOF), a resource for investors and traders seeking the latest updates and insights on Diagnos stock.
DIAGNOS Inc. (DGNOF) is a publicly traded Canadian corporation that focuses on the early detection of critical health and eye-related problems using Artificial Intelligence. Its disclosures highlight the FLAIRE AI platform and applications such as CARA (Computer Assisted Retina Analysis), which support retinal image analysis, mass screening, and clinical decision-making for ocular diseases.
This news page aggregates coverage of DIAGNOS’ activities, including announcements about AI-driven retinal diagnostics, partnerships, research presentations, and corporate events. Recent news has described the company’s participation in investor conferences, such as Centurion One Capital growth events, where DIAGNOS presents its AI solution for the medical market and discusses the potential of its technology.
Readers can also find updates on collaborations with clinical and research partners. For example, DIAGNOS has reported on the launch of “IRIS-ai powered by DIAGNOS” with IRIS, The Visual Group, and on joint research with École de Technologie Supérieure (ÉTS) on mass screening for macular edema using Optical Coherence Tomography. These items provide insight into how the company’s algorithms are trained, validated, and applied in real-world settings.
News items may discuss regulatory aspects related to CARA and the FLAIRE platform, developments in the retinal diagnostics market, and DIAGNOS’ efforts to expand the use of its AI technology. Investors and observers can use this page to follow corporate communications, product and research milestones, and participation in industry and investor conferences related to AI-based medical imaging and eye health.
DIAGNOS (OTCQB: DGNOF) will present at the Centurion One Capital 3rd Annual Bahamas Summit on October 28–29, 2025 at the Rosewood Baha Mar Hotel in Nassau. CEO André Larente will present, attend investor meetings and participate on a panel.
The company noted a successful MDSAP audit and referenced pending regulatory approvals from Saudi FDA, Health Canada and the FDA. The summit runs 9:00 AM–5:00 PM EDT and features presentations, 1x1 investor meetings and panel discussions.
DIAGNOS Inc. (TSXV: ADK) (OTCQB: DGNOF), a pioneer in AI-driven health detection through its FLAIRE platform, will present at the Centurion One Capital 8th Annual Conference in Toronto on March 6th, 2025. The private event connects Canadian investors with promising investment opportunities.
CEO André Larente emphasized that AI will enhance medical practice by improving accuracy and efficiency. The company's focus is on revolutionizing eye health through AI technologies, particularly in the optometry market which includes over 300,000 sites globally. Their CARA (Computer Assisted Retina Analysis) system provides enhanced retinal image analysis for efficient patient screening.
DIAGNOS has recently secured a partnership with the industry's largest player, validating their technology and expanding their market presence. The company is also seeing a revival in government-related business initiatives, indicating a growth phase.
Summary not available.
Diagnos Inc. (OTCQB: DGNOF) is poised to revolutionize macular edema screening through its AI-based FLAIRE platform. In collaboration with École de Technologie Supérieure (ÉTS), Diagnos will present innovative research at ARVO 2023, aimed at enhancing mass screening efficiency using Optical Coherence Tomography (OCT). This groundbreaking study reduces false positives and improves the speed and accessibility of detection, addressing a major cause of vision loss in diabetics and AMD patients. With the OCT market expanding rapidly, Diagnos is well-positioned for success, reflecting its commitment to medical imaging innovation.
DIAGNOS Inc. (OTCQB: DGNOF) is expanding into the retinal diagnostics market with its advanced 3D image analysis technology. This innovative platform diagnoses retinal conditions like Age-Related Macular Degeneration and Glaucoma, while also identifying systemic diseases like Alzheimer’s and cardiovascular diseases. The technology combines retinal images and OCT scans, offering superior accuracy over MRI and ultrasound. Market trends show increasing healthcare adoption of retinal imaging and reimbursement policies, as DIAGNOS aims to capitalize on the sector's growth potential.